Yajun Duan Selected Research

Atherosclerotic Plaque (Atheroma)

1/2022	MEK1/2 inhibitor inhibits neointima formation by activating miR-126-3p/ C-X-C motif chemokine ligand 12 (CXCL12)/C-X-C motif chemokine receptor 4 (CXCR4) axis.
1/2020	Combination of MEK1/2 inhibitor and LXR ligand synergistically inhibit atherosclerosis in LDLR deficient mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yajun Duan Research Topics

Disease

36	Atherosclerosis 12/2023 - 06/2012
23	Inflammation (Inflammations) 12/2023 - 04/2014
19	Neoplasms (Cancer) 04/2024 - 04/2008
11	Cardiovascular Diseases (Cardiovascular Disease) 04/2024 - 01/2015
8	Breast Neoplasms (Breast Cancer) 04/2024 - 05/2015
8	Vascular Calcification 04/2024 - 10/2018
8	Insulin Resistance 03/2024 - 01/2019
8	Fatty Liver 01/2022 - 01/2018
6	Heart Failure 10/2023 - 03/2020
5	Carcinoma (Carcinomatosis) 12/2023 - 04/2014
5	Coronary Disease (Coronary Heart Disease) 08/2023 - 05/2014
4	Fibrosis (Cirrhosis) 03/2023 - 11/2019
4	Hypercholesterolemia 03/2023 - 01/2017
4	Hypertriglyceridemia 01/2023 - 04/2015
3	Neoplasm Metastasis (Metastasis) 12/2023 - 01/2016
3	Obesity 04/2023 - 01/2020
3	Necrosis 01/2023 - 11/2019
3	Cholestasis 01/2023 - 01/2020
3	Prostatic Neoplasms (Prostate Cancer) 01/2023 - 09/2022
3	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2021 - 01/2018
3	Non-alcoholic Fatty Liver Disease 12/2020 - 02/2018
3	Vascular Diseases (Vascular Disease) 03/2020 - 01/2019
3	Dyslipidemias (Dyslipidemia) 01/2020 - 04/2015
2	Hemorrhage 01/2023 - 01/2019
2	Mitochondrial Diseases (Mitochondrial Disease) 09/2022 - 11/2021
2	Atherosclerotic Plaque (Atheroma) 01/2022 - 01/2020
2	Sepsis (Septicemia) 12/2021 - 08/2021
2	Virus Diseases (Viral Diseases) 11/2021 - 12/2018
2	Wounds and Injuries (Trauma) 06/2021 - 01/2017
2	Cardiotoxicity 06/2021 - 12/2020
2	Atrophy 03/2021 - 01/2021
2	Parkinson Disease (Parkinson's Disease) 01/2021 - 01/2019

Drug/Important Bio-Agent (IBA)

20	Apolipoproteins E (ApoE)IBA 04/2024 - 04/2015
17	LipidsIBA 03/2024 - 06/2013
11	LigandsIBA 04/2024 - 12/2010
10	CholesterolIBA 12/2023 - 12/2012
9	Glucose (Dextrose)FDA LinkGeneric 12/2023 - 06/2015
9	Liver X ReceptorsIBA 01/2021 - 12/2012
9	Capsules (Microcapsules)IBA 01/2021 - 01/2015
7	T0901317IBA 01/2021 - 04/2014
7	naoxintongIBA 01/2021 - 01/2015
6	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2023 - 03/2020
6	ApolipoproteinsIBA 03/2023 - 05/2014
5	AntioxidantsIBA 10/2023 - 09/2015
5	Proteins (Proteins, Gene)FDA Link 08/2023 - 01/2018
5	Rosiglitazone (Avandia)FDA Link 01/2023 - 11/2019
5	oxidized low density lipoproteinIBA 01/2023 - 12/2012
5	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2022 - 03/2020
5	U 0126 (UO 126)IBA 01/2022 - 02/2015
5	CollagenIBA 03/2021 - 05/2015
4	Triglycerides (Triacylglycerol)IBA 01/2023 - 01/2019
4	Transcription Factors (Transcription Factor)IBA 06/2021 - 12/2012
4	LongShengZhiIBA 03/2020 - 01/2019
4	Tamoxifen FDA LinkGeneric 12/2018 - 05/2015
3	EnzymesIBA 04/2024 - 03/2020
3	CateninsIBA 04/2024 - 07/2023
3	danshen dripping pillIBA 04/2024 - 06/2021
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2024 - 01/2021
3	pterostilbeneIBA 12/2023 - 08/2021
3	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 12/2023 - 12/2020
3	CytokinesIBA 10/2023 - 11/2019
3	Biomarkers (Surrogate Marker)IBA 08/2023 - 12/2010
3	IsoflavonesIBA 04/2023 - 01/2020
3	LDL Receptors (LDL Receptor)IBA 03/2023 - 05/2014
3	AdiponectinIBA 01/2023 - 01/2017
3	Small Interfering RNA (siRNA)IBA 01/2022 - 12/2018
3	Monoamine Oxidase (MAO)IBA 11/2021 - 01/2019
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2021 - 11/2019
3	Collagen Type I (Type I Collagen)IBA 03/2021 - 11/2019
3	Transforming Growth Factors (Transforming Growth Factor)IBA 03/2021 - 11/2019
3	Peptides (Polypeptides)IBA 01/2021 - 12/2010
3	InterferonsIBA 01/2021 - 02/2015
3	Estrogen ReceptorsIBA 12/2018 - 10/2018
3	Teniposide (VM 26)FDA Link 12/2018 - 06/2013
3	trioctyl phosphine oxide (TOPO)IBA 12/2018 - 06/2013
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 02/2018 - 08/2015
3	buchang naoxintongIBA 01/2017 - 01/2015
3	Fatty Acid-Binding ProteinsIBA 08/2015 - 06/2012
2	CalciumIBA 04/2024 - 12/2023
2	Carrier Proteins (Binding Protein)IBA 03/2024 - 01/2022
2	CarbohydratesIBA 03/2024 - 12/2020
2	Therapeutic UsesIBA 03/2024 - 01/2019
2	pitavastatin (itavastatin)FDA Link 01/2024 - 08/2015
2	Streptozocin (Streptozotocin)FDA Link 12/2023 - 01/2021
2	fibroblast growth factor 21IBA 12/2023 - 12/2020
2	KetonesIBA 12/2023 - 09/2022
2	Ethanol (Ethyl Alcohol)IBA 04/2023 - 01/2020
2	Alkaline PhosphataseIBA 01/2023 - 11/2019
2	AMP-Activated Protein KinasesIBA 01/2023 - 01/2018
2	Blood Glucose (Blood Sugar)IBA 01/2023 - 01/2021
2	Bile Acids and Salts (Bile Acids)IBA 01/2023 - 03/2021
2	Sirtuin 3IBA 09/2022 - 03/2020
2	Toll-Like Receptor 4IBA 03/2021 - 01/2021
2	CatalaseIBA 03/2021 - 03/2020
2	Glutathione PeroxidaseIBA 03/2021 - 01/2020
2	Glutamic Acid (Glutamate)FDA Link 01/2021 - 01/2020
2	Urethane (Ethyl Carbamate)IBA 01/2021 - 01/2016

Therapy/Procedure

8	Chinese Traditional Medicine (Traditional Chinese Medicine) 03/2024 - 01/2019
6	Therapeutics 03/2023 - 04/2015
2	Oral Administration 01/2021 - 01/2021